drugset / Trial / NCT06790784
Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR
Phase 3
Recruiting
426 enrolled
Jaeb Center for Health Research
Genentech, Inc. · collabNational Eye Institute (NEI) · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
This randomized trial will compare treatment strategies for proliferative diabetic retinopathy (PDR). Participants will receive either combination a of faricimab + PRP or vitrectomy + endolaser. The participants will be followed for 3 years. The study will evaluate long-term visual acuity as well as differences in number of injections, procedures, and complications during follow-up (after completion of randomization treatment), and cost.
Timeline
- Start
- 2025-08-04
- Primary completion
- 2031-08
- Completion
- 2031-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Faricimab | Monoclonal antibody | — | — |